SII Seeks Govt’s Nod To Manufacture, Stockpile qHPV Vaccine Against Cervical Cancer
![The SII will soon seek market authorisation as well as a manufacturing licence from the Drugs Controller General of India (DCGI) for the vaccine.](https://healthwire.co/wp-content/uploads/2022/05/SII.jpg)
The application mentions that every year, lakhs of women are diagnosed with cervical cancer and the death ratio is also very high. In India, cervical cancer ranks as the second most frequent cancer among women in the 15-44 age group.
Share